Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

Fig. 6

Accentuation of Nrf2 augments the chemoresistance of GEM. a The cell viability was determined using MTT assay after treatment with tBHQ, GEM or their combination for 48 h. b Effects of Nrf2 activation on protein levels of HO-1, NQO1, γGCSm and AKR1B10 in Miapaca-2 and Capan-2 cells following tBHQ, GEM or their combination treatment. c Schematic design of the experiments on the orthotopic PDAC mouse model. d Representative tumor images, and the tumor volume (f) and tumor weight (g). e The body weight of each group of the animals (n = 6). (h-i). Representative images of H&E and IHC staining of Nrf2, Ki-67 and NQO1 in the tumor tissues (Scale bar: 20 μm). Data were presented as the mean ± SD. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the control group. #p < 0.05, ###p < 0.001 compared with the GEM alone treatment group

Back to article page